5-nitrobenzimidazole-6-carboxylic acid | 130148-51-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-nitrobenzimidazole-6-carboxylic acid
• 英文别名: 5-nitro-1H-benzoimidazole-6-carboxylic acid；5-nitro-1H-1,3-benzodiazole-6-carboxylic acid；6-nitro-1H-benzimidazole-5-carboxylic acid
• CAS: 130148-51-5
• 化学式: C₈H₅N₃O₄
• 分子量: 207.145
• InChiKey: CHISOTCWJMFPPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  112
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-nitrobenzimidazole-6-carboxylic acid 在 palladium on activated charcoal 氯化亚砜 、 氢气 作用下， 反应 12.17h， 生成 7-methylimidazo<4,5-g>quinazolin-8-(3H,7H)-one
  参考文献：
  名称：

  Regioselective synthesis of imidazo[4,5-g]quinazoline quinone nucleosides and quinazoline amino nucleosides. Studies of their xanthine oxidase and purine nucleoside phosphorylase substrate activity

  摘要：

  The regioselective synthesis of 3-ribofuranosylimidazo[4,5-g]quinazoline-4,8-9(3H,7H)-trione (1) (benzoquinone-stretched-out inosine) and 8-(ribofuranosylamino)quinaozlin-4(3G)-one (2) was carried out in conjunction with the design of reductive alkylating nuclosides and new purine nucleoside mimics, respectively. The preparation of 1 was carried out by regioselective ribosylation of 4-nitroimidazo[4,5-g]quinazolin-8(3H,7H)-one (3) followed by nitro group reduction, Fremy oxidation, and deacetylation. Regiocontrol of ribosylation has steric origions: the 4-nitro group of 3 directs silylation to the N(1) position, which results in ribosylation exclusively at the N(3) position under Vorbruggen reaction conditions. Regiocontrol during the preparation of 2 was possible by generating a stabilized ribofuranosyl carbocation, which selectively reacts with the amine group of the base. Nucleoside 1 is a purine-like quinone by virtue of its oxidation by xanthine oxidase. The potential inosine mimic 2 does not undergo phosphorolysis by purine nucleoside phosphorylase (PNPase), but the base form (8-amino-quinazolin-4(3H)-one) does bind to the PNPase active site as tightly as hypoxanthine. Factors which contribute to this binding behavior are discussed.

  DOI：

  10.1021/jo00002a052
• 作为产物：
  描述：

  1H-苯并咪唑-5-羧酸 在 硫酸 、 硝酸 作用下， 反应 1.0h， 以66%的产率得到5-nitrobenzimidazole-6-carboxylic acid
  参考文献：
  名称：

  Quinazoline derivatives and therapeutic use thereof

  摘要：

  描述了由一般式表示的喹唑啉衍生物及其药理学可接受的盐，以及含有这些化合物的组合物。还描述了使用这些化合物治疗过度增生性疾病的方法。

  公开号：

  US20050187231A1

文献信息

• [EN] BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS<br/>[FR] DÉRIVÉS HÉTÉROARYLE BICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE L'ECTONUCLÉOTIDE PYROPHOSPHATASE/PHOSPHODIESTÉRASE 1
  申请人：RIBOSCIENCE LLC

  公开号：WO2020210649A1

  公开（公告）日：2020-10-15

  The present disclosure provides certain bicyclic heteroaryl compounds that inhibit ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzymatic activity and are therefore useful for the treatment of diseases and conditions modulated at least in part by ENPP1. In some embodiments, the bicyclic heteroaryl compounds includes those of Formula (I). Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本公开提供了一些抑制细胞外核苷酸焦磷酸酶/磷酸二酯酶1（ENPP1）酶活性的双环杂环芳基化合物，因此对于治疗至少部分受ENPP1调节的疾病和病况是有用的。在某些实施例中，双环杂环芳基化合物包括式（I）中的化合物。本文还提供了含有这类化合物的药物组合物以及制备这类化合物的方法。
• Quinazoline Derivatives and Therapeutic Use Thereof
  申请人：Lee Young B.

  公开号：US20090030021A1

  公开（公告）日：2009-01-29

  Quinazoline derivatives represented by the general formula pharmacologically acceptable salts thereof, and compositions containing such compounds are described. Methods for using the compounds for treatment of hyperproliferative disorders are also disclosed.

  本发明涉及一般式所代表的喹唑啉衍生物，其药物学上可接受的盐以及含有这些化合物的组合物。还公开了使用这些化合物治疗过度增殖性疾病的方法。
• Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3
  申请人：Kearney Patrick

  公开号：US20090042918A1

  公开（公告）日：2009-02-12

  Compounds of formula (I), useful for inhibiting PIM-I and/or PIM-3: and pharmaceutically acceptable salts thereof, wherein Y, Z, R 1 , R 3 , Q, X and R 4 are as defined above. Pharmaceutical compositions and methods of treating diseases and conditions, such as cancer, are also disclosed.

  式(I)的化合物，用于抑制PIM-I和/或PIM-3：及其药学上可接受的盐，其中Y，Z，R1，R3，Q，X和R4如上所定义。还公开了药物组合物和治疗疾病和病症（如癌症）的方法。
• WO2007/44724
  申请人：——

  公开号：——

  公开（公告）日：——
• OHARA, DEMPCY ROBERT;SKIBO, EDWARD B., J. ORG. CHEM., 56,(1991) N, C. 776-785
  作者：OHARA, DEMPCY ROBERT、SKIBO, EDWARD B.

  DOI：——

  日期：——